Clear Search

Showing 1 result for “Zeeuw DD” published 2022.

January 2022

Effects of canagliflozin with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c disease duration and treatment intensity: results from the CANVAS program

Diabetologia. 2021;64:2402–14 doi.org/10.1007/s00125-021-05524-1

This study by Young et al. shows canagliflozin to have beneficial CV and kidney outcomes in patients with T2DM across a range of diabetes complexities with an underlying risk of CV disease.

more…